Secondary analysis of FIBRONEER-ILD in 325 patients with autoimmune disease-related progressive pulmonary fibrosis: 52-week FVC decline was smaller with nerandomilast 9 mg and 18 mg than placebo (-61, -65 vs -107 mL; CIs crossed zero); HR for death 0.40 and 0.28.
Secondary analysisn = 325
Hoffmann-Vold et al. Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial